{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:58:50Z","timestamp":1789754330473,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.ejphar.2007.09.025","type":"journal-article","created":{"date-parts":[[2007,10,3]],"date-time":"2007-10-03T11:12:27Z","timestamp":1191409947000},"page":"142-147","source":"Crossref","is-referenced-by-count":10,"title":["Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes"],"prefix":"10.1016","volume":"578","author":[{"given":"Amine","family":"Benyamina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Arbus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Nuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo P.","family":"Garay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gervais","family":"Neliat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahc\u00e8ne","family":"Hameg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2007.09.025_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s002130050010","article-title":"5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity","volume":"147","author":"Alvarez-Guerra","year":"2000","journal-title":"Psychopharmacol. (Berl)"},{"key":"10.1016\/j.ejphar.2007.09.025_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0014-2999(02)02489-5","article-title":"5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle","volume":"454","author":"Alvarez-Guerra","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1476-5381.1995.tb14977.x","article-title":"The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors","volume":"115","author":"Bonhaus","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0166-4328(01)00238-8","article-title":"Cyamemazine as an anxiolytic drug on the elevated plus maze and light\/dark paradigm in mice","volume":"124","author":"Bourin","year":"2001","journal-title":"Behavioural Brain Res."},{"key":"10.1016\/j.ejphar.2007.09.025_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1527-3458.2004.tb00023.x","article-title":"Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome.","volume":"10","author":"Bourin","year":"2004","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejphar.2007.09.025_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1476-5381.1983.tb09380.x","article-title":"Characteristics of GABAB receptor binding sites on rat whole brain synaptic membranes","volume":"78","author":"Bowery","year":"1983","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib7","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF01993161","article-title":"Heterogeneity of [3H]-mepyramine binding sites in guinea pig cerebellum and lung","volume":"33","author":"Dini","year":"1991","journal-title":"Agents Actions"},{"key":"10.1016\/j.ejphar.2007.09.025_bib9","first-page":"727","article-title":"Antagonist binding profiles of five cloned human muscarinic receptor subtypes","volume":"256","author":"Dorje","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2007.09.025_bib10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/hup.718","article-title":"Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome","volume":"20","author":"Favre","year":"2005","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib11","doi-asserted-by":"crossref","first-page":"9762","DOI":"10.1073\/pnas.86.24.9762","article-title":"Cloning of the cDNA and gene for a human D2 dopamine receptor","volume":"86","author":"Grandy","year":"1989","journal-title":"Proc. Natl. Acad. Sci. (USA)"},{"key":"10.1016\/j.ejphar.2007.09.025_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-2999(79)90202-4","article-title":"Binding characteristics of [3H]-prazosin to rat brain alpha-adrenergic receptors","volume":"55","author":"Greengrass","year":"1979","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib13","first-page":"503","article-title":"Prescription d'antipsychotiques en milieu hospitalier sp\u00e9cialis\u00e9","volume":"82","author":"Gury","year":"2006","journal-title":"Inf. Psychiatr."},{"key":"10.1016\/j.ejphar.2007.09.025_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0006-2952(02)01515-0","article-title":"Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes","volume":"65","author":"Hameg","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2222.1999.0290s3133.x","article-title":"Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects","volume":"29","author":"Hindmarch","year":"1999","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.ejphar.2007.09.025_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00213-005-2172-z","article-title":"A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian)","volume":"180","author":"Hode","year":"2005","journal-title":"Psychopharmacol. (Berl)"},{"key":"10.1016\/j.ejphar.2007.09.025_bib17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1476-5381.1996.tb15529.x","article-title":"Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-As) subunit stably expressed in HEK 293 cells","volume":"118","author":"Hope","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pnpbp.2005.08.015","article-title":"Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome","volume":"30","author":"Lemoine","year":"2006","journal-title":"Progress Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2007.09.025_bib19","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.pnpbp.2006.02.013","article-title":"Effects of activation and blockade of 5-HT2A\/2C receptors in the dorsal raphe nucleus on sleep and waking in the rat","volume":"30","author":"Monti","year":"2006","journal-title":"Progress Neuro-Psychopharmacol. Biological Psychiatry"},{"key":"10.1016\/j.ejphar.2007.09.025_bib20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1211\/0022357044346","article-title":"Cloned human 5-HT1A receptor pharmacology determined using agonist binding and measurement of cAMP accumulation","volume":"56","author":"Najam","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00210-002-0665-4","article-title":"Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine","volume":"367","author":"Peinado","year":"2003","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib22","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1002\/j.1460-2075.1987.tb02733.x","article-title":"Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors","volume":"6","author":"Peralta","year":"1987","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2007.09.025_bib23","doi-asserted-by":"crossref","first-page":"18200","DOI":"10.1016\/S0021-9258(17)46830-X","article-title":"Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype","volume":"68","author":"Shen","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2007.09.025_bib24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/273392a0","article-title":"Use of [3H]muscimol for GABA receptor studies","volume":"273","author":"Snodgrass","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2007.09.025_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0922-4106(94)90042-6","article-title":"Genomic organisation and functional expression of the gene encoding the human serotonin 5-HT2C receptor. European Journal of Pharmacology","volume":"269","author":"Stam","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1600-0773.1991.tb01308.x","article-title":"Rat spinal chord alpha2-adrenoceptors are of the alpha2A-subtype : comparison with alpha2A and alpha2B-adrenoceptors in rat spleen, cerebral cortex and kidney using 3H-RX821002 ligand binding","volume":"69","author":"Uhlen","year":"1991","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2007.09.025_bib27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/358149a0","article-title":"Multiple dopamine D4 receptor variants in the human population","volume":"358","author":"Van Tol","year":"1992","journal-title":"Nature"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907010539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907010539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T03:15:34Z","timestamp":1629861334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299907010539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":27,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0014299907010539"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2007.09.025","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}